Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
The other considerations weight more heavily. There are likely some cost savings due to economies of scale, although that would be difficult to test for in a product such as Viagra, which has enjoyed strong sales its entire existence, and for which specific production cost data is unavailable.
With respect to Viagra, Pfizer is operating in a constant returns to scale environment. The market for Viagra has been slow growing in recent years, and at a high level. The changes in demand for Viagra are of such small size that they are unlikely to have a significant impact on production costs. The primary impact of economies of scale is with respect to the manner in which drug companies exploit the high margins they can earn on blockbuster drugs to finance their operations. Even with this, the contribution that these drugs make is based less on the ability of the company to control production costs by building economies of scale than it is on the company's patent protections which allow them to exploit low price elasticity of demand.
Economies of scope are more significant for the pharmaceutical industry. A product such as Viagra is used to lower the average development...
Production cost in this scenario is largely irrelevant, but the primary cost driver of development is borne by one successful product such as Viagra, but spread over several other products that did not make it to market. Indeed, faced with the loss of patent protection of Viagra, Lipitor and other major income earners, Pfizer has had to lower its R&D costs (Goldstein, 2010) because it is unable to take advantage of economies of scope without the high revenues that patent protection earns marketable products like Viagra.
Works Cited:
Goldstein, J. (2010). Pfizer plans to cut billions in annual R&D spending. Wall Street Journal. Retrieved November 17, 2010 from http://blogs.wsj.com/health/2010/02/03/pfizer-plans-to-cut-billions-in-annual-rd-spending/
Outsourcing Pharma. (2003). Drug development costs hit $1.7 billion. Outsourcing Pharma. Retrieved November 17, 2010 from http://www.outsourcing-pharma.com/Preclinical-Research/Drug-development-costs-hit-1.7-billion
Pfizer Financial Report 2009. Retrieved November 17, 2010 from http://media.pfizer.com/files/annualreport/2009/financial/financial2009.pdf
Works Cited:
Goldstein, J. (2010). Pfizer plans to cut billions in annual R&D spending. Wall Street Journal. Retrieved November 17, 2010 from http://blogs.wsj.com/health/2010/02/03/pfizer-plans-to-cut-billions-in-annual-rd-spending/
Outsourcing Pharma. (2003). Drug development costs hit $1.7 billion. Outsourcing Pharma. Retrieved November 17, 2010 from http://www.outsourcing-pharma.com/Preclinical-Research/Drug-development-costs-hit-1.7-billion
Pfizer Financial Report 2009. Retrieved November 17, 2010 from http://media.pfizer.com/files/annualreport/2009/financial/financial2009.pdf
Pfizer The Economics of the Pharmaceutical Industry -- Focus on Pfizer Drugs Specify on some background of the company According to its official website, Pfizer Incorporated "discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has
The return on assets was 7.3% last year, up slightly from 7.1% the year before. Again, the metric has fluctuated and 7.3% is in the middle. These figures indicate that Pfizer's returns are about average. Aside from an unusually good year in 2007 with respect to their returns, the company is rangebound in terms of its managerial efficiency. Recapturing the 2007 successes would be more encouraging but at present there
Also cited as threats are those of: (1) Product manufacturing and marketing risks; (2) Cost and expense control or unusual events; and (3) Changes in laws and accounting standards. (Pfizer Inc. Report to the United States Securities and Exchange Commission, 2008) IV. Internal Environment -- Strength and Weaknesses Stated as strengths of Pfizer Inc. are the following components of its organization: (1) Written policies and procedures; (2) a compliance officer and compliance committee; (3) Effective training
Pfizer's Batch Process Design Model Pfizer is a global pharmaceutical manufacturer heavily invested in drug discovery (Pfizer, 2013a). Accordingly, the supply chain needs of Pfizer are atypical of most manufacturers because a significant portion of its production activities must be tailored to meet the needs of researchers investigating the efficacy of drugs in clinical trials. The needs of the research and development arm of Pfizer therefore dominate the process development structure
Although advertising costs can be substantial, it is essential that companies place significant amounts of funding into advertising. Such funding is necessary because it provides companies with a competitive advantage. According to Doraszelski & Markovich, (2007) "Practitioners know very well the value of advertising to achieving their long-term market share and profitability goals. A survey of senior executives in 1999 reveals that 82.9% somewhat or strongly agree that good advertising can
Q1.Why has the attractiveness of the pharmaceutical industry declined so much since the 1980’s? What are the implications of those changes in industry structure for firm strategy? Despite the tremendous profits garnered by large pharmaceutical companies for so-called blockbuster drugs, pharmaceutical companies must make huge investments in R&D to produce profitable medications. The vast majority of drugs which are developed and tested never go to market. Additionally, once companies produce valuable